$TCRT
Alaunos Therapeutics, Inc.

2018 Q4 Form 10-Q Financial Statement

#000119312518323155 Filed on November 09, 2018

View on sec.gov

Income Statement

Concept 2018 Q4 2018 Q3 2017 Q3
Revenue $0.00 $0.00 $1.598M
YoY Change -100.0% -100.0% -0.13%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.560M $4.310M $3.570M
YoY Change 18.44% 20.73% 0.85%
% of Gross Profit
Research & Development $8.200M $8.263M $11.11M
YoY Change -26.65% -25.59% 23.73%
% of Gross Profit
Depreciation & Amortization $170.0K $150.0K $90.00K
YoY Change 54.55% 66.67% 28.57%
% of Gross Profit
Operating Expenses $12.76M $12.57M $11.11M
YoY Change -15.1% 13.19% 23.73%
Operating Profit -$12.76M -$12.57M -$13.08M
YoY Change -5.02% -3.88% 19.83%
Interest Expense $110.0K -$170.0K $200.0K
YoY Change -185.0% 900.0%
% of Operating Profit
Other Income/Expense, Net $170.0K $150.0K $175.0K
YoY Change 0.0% -14.29% 348.72%
Pretax Income -$12.48M -$12.59M -$12.70M
YoY Change -5.95% -0.87% 17.05%
Income Tax
% Of Pretax Income
Net Earnings $194.5M -$18.66M -$17.60M
YoY Change -1164.68% 5.99% 21.87%
Net Earnings / Revenue -1101.63%
Basic Earnings Per Share $1.29 -$0.13
Diluted Earnings Per Share $1.29 -$0.13 -$0.13
COMMON SHARES
Basic Shares Outstanding 142.4M shares 142.4M shares 142.0M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q4 2018 Q3 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $61.70M $31.70M $84.40M
YoY Change -12.98% -62.44% -10.88%
Cash & Equivalents $61.73M $31.73M $84.41M
Short-Term Investments
Other Short-Term Assets $20.70M $14.40M $30.50M
YoY Change 4.55% -52.79% 45.24%
Inventory
Prepaid Expenses
Receivables $1.900M $1.000M $0.00
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $84.29M $47.16M $114.9M
YoY Change -7.16% -58.95% -0.68%
LONG-TERM ASSETS
Property, Plant & Equipment $1.097M $1.344M $1.047M
YoY Change -9.41% 28.37% 26.91%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $9.541M $18.17M $496.0K
YoY Change -29.24% 3562.9% 0.81%
Total Long-Term Assets $10.77M $19.64M $1.671M
YoY Change -27.37% 1075.34% 15.64%
TOTAL ASSETS
Total Short-Term Assets $84.29M $47.16M $114.9M
Total Long-Term Assets $10.77M $19.64M $1.671M
Total Assets $95.05M $66.80M $116.6M
YoY Change -9.99% -42.69% -0.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $707.0K $1.269M $1.524M
YoY Change -83.99% -16.73% -15.99%
Accrued Expenses $8.763M $9.377M $10.11M
YoY Change -11.57% -7.25% 37.29%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.483M $60.18M $18.19M
YoY Change -54.53% 230.88% 15.53%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $2.600M $39.10M
YoY Change -100.0% -93.35% -11.14%
Total Long-Term Liabilities $0.00 $2.600M $39.10M
YoY Change -100.0% -93.35% -11.14%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.483M $60.18M $18.19M
Total Long-Term Liabilities $0.00 $2.600M $39.10M
Total Liabilities $9.487M $62.79M $57.29M
YoY Change -83.76% 9.6% -4.08%
SHAREHOLDERS EQUITY
Retained Earnings -$566.3M -$761.2M -$699.2M
YoY Change -20.51% 8.87% 8.1%
Common Stock $651.9M $604.8M $619.4M
YoY Change 5.89% -2.35% 6.36%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $85.56M -$156.4M -$79.80M
YoY Change
Total Liabilities & Shareholders Equity $95.05M $66.80M $116.6M
YoY Change -9.99% -42.69% -0.48%

Cashflow Statement

Concept 2018 Q4 2018 Q3 2017 Q3
OPERATING ACTIVITIES
Net Income $194.5M -$18.66M -$17.60M
YoY Change -1164.68% 5.99% 21.87%
Depreciation, Depletion And Amortization $170.0K $150.0K $90.00K
YoY Change 54.55% 66.67% 28.57%
Cash From Operating Activities -$11.82M -$8.510M -$12.71M
YoY Change -2.8% -33.04% -9.92%
INVESTING ACTIVITIES
Capital Expenditures -$90.00K $170.0K $70.00K
YoY Change -132.14% 142.86% -66.67%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $90.00K -$170.0K -$70.00K
YoY Change -132.14% 142.86% -66.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 41.35M 0.000 0.000
YoY Change -4114.56%
NET CHANGE
Cash From Operating Activities -11.82M -8.510M -12.71M
Cash From Investing Activities 90.00K -170.0K -70.00K
Cash From Financing Activities 41.35M 0.000 0.000
Net Change In Cash 29.62M -8.680M -12.78M
YoY Change -319.9% -32.08% -10.75%
FREE CASH FLOW
Cash From Operating Activities -$11.82M -$8.510M -$12.71M
Capital Expenditures -$90.00K $170.0K $70.00K
Free Cash Flow -$11.73M -$8.680M -$12.78M
YoY Change -5.71% -32.08% -10.75%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
142379770 shares
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
84406000
CY2017Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84794000
CY2017Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
388000
CY2018Q1 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
2469000
CY2018Q2 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
2358000
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1269000
CY2018Q3 us-gaap Assets
Assets
66801000
CY2018Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9377000
CY2018Q3 us-gaap Assets Current
AssetsCurrent
47161000
CY2018Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
604653000
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31728000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32117000
CY2018Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
142379770 shares
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
142379770 shares
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
142000
CY2018Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
6000
CY2018Q3 us-gaap Deferred Rent Credit
DeferredRentCredit
30000
CY2018Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
498000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
576000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2924501 shares
CY2018Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
49513000
CY2018Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2597000
CY2018Q3 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
24000
CY2018Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
128000
CY2018Q3 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
2597000
CY2018Q3 us-gaap Liabilities
Liabilities
62786000
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
66801000
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
60183000
CY2018Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
18168000
CY2018Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2018Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14412000
CY2018Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
389000
CY2018Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
0
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1344000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
5053295 shares
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-761209000
CY2018Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
1021000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.13
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4069468 shares
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.24
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
-156414000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
81441000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4417000
CY2017Q4 us-gaap Assets
Assets
105606000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9909000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
90783000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
615493000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70946000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
71335000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
142658037 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
142658037 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
143000
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1000
CY2017Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
142000
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6389000
CY2017Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2424000
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
141000
CY2017Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
35139000
CY2017Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
128000
CY2017Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
2424000
CY2017Q4 us-gaap Liabilities
Liabilities
58420000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
105606000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
20856000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
13484000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
19818000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1211000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-712442000
CY2017Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
19000
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1152000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2925502 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.12
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3852135 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.12
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-96806000
CY2018Q3 ziop Accelerated Shares Vested Restricted Shares
AcceleratedSharesVestedRestrictedShares
34516 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27851409 shares
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3353000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1292000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
259000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-4792000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
3000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10946000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1368000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-102000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6660000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-8000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1002000
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-461000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
46327000
us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
1042000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-54989000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-42513000
us-gaap Net Income Loss
NetIncomeLoss
-41050000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
299000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
461000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
44849000
us-gaap Operating Income Loss
OperatingIncomeLoss
-40057000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
545000
us-gaap Profit Loss
ProfitLoss
-41050000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
13939000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
99000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
47270000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.34
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4792000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33903000
us-gaap Share Based Compensation
ShareBasedCompensation
6165000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
859000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
135689364 shares
dei Amendment Flag
AmendmentFlag
false
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
58317741 shares
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6850000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-39218000
us-gaap Cumulative Effect On Retained Earnings Net Of Tax1
CumulativeEffectOnRetainedEarningsNetOfTax1
-8131000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
46000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
412000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
dei Document Type
DocumentType
10-Q
us-gaap Dividends Preferred Stock
DividendsPreferredStock
16656000
dei Entity Registrant Name
EntityRegistrantName
ZIOPHARM ONCOLOGY INC
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Central Index Key
EntityCentralIndexKey
0001107421
dei Document Period End Date
DocumentPeriodEndDate
2018-09-30
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-146000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
4684000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15355000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3148000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-112000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5406000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
1002000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-532000
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-545000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1035000
us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
1275000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-57292000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37638000
us-gaap Net Income Loss
NetIncomeLoss
-40636000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
462000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
545000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
41290000
us-gaap Operating Income Loss
OperatingIncomeLoss
-41144000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
534000
us-gaap Profit Loss
ProfitLoss
-40636000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
16656000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
240000
CY2017Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17604000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-12701000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y11M23D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
184500 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.49
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
146000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
146000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25935000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.77
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.50
us-gaap Share Based Compensation
ShareBasedCompensation
6850000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y2M1D
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.30
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
240000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
506000 shares
us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
1275000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
506000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
141020025 shares
dei Trading Symbol
TradingSymbol
ZIOP
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
104167 shares
us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
0
ziop Additional Share Based Compensation Expense
AdditionalShareBasedCompensationExpense
481000
ziop Accelerated Vested Restricted Stock Adjustment
AcceleratedVestedRestrictedStockAdjustment
12000
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y6M29D
CY2018Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
28000
CY2018Q1 ziop Embedded Derivative Dividend Amount
EmbeddedDerivativeDividendAmount
73000
CY2018Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
183000
CY2018Q2 ziop Embedded Derivative Dividend Amount
EmbeddedDerivativeDividendAmount
72000
CY2017Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
202000
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3571000
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
175000
CY2017Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
14676000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13078000
CY2017Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
177000
CY2017Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
4903000
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8082 pure
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0188 pure
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.29
CY2017Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1598000
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11105000
CY2017Q3 us-gaap Share Based Compensation
ShareBasedCompensation
2082000
CY2017Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8095 pure
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
593500 shares
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0201 pure
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
140632297 shares
CY2018Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-165000
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4307000
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-18659000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-12585000
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
150000
CY2018Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
12570000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12570000
CY2018Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
145000
CY2018Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
6074000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8227 pure
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0282 pure
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.11
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8263000
CY2018Q3 us-gaap Share Based Compensation
ShareBasedCompensation
1480000
CY2018Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8308 pure
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
300500 shares
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0298 pure
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
141185404 shares
CY2018Q3 ziop Embedded Derivative Dividend Amount
EmbeddedDerivativeDividendAmount
74000
CY2018Q3 ziop Accelerated Vested Restricted Stock Adjustment
AcceleratedVestedRestrictedStockAdjustment
12000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
40000

Files In Submission

Name View Source Status
0001193125-18-323155-index-headers.html Edgar Link pending
0001193125-18-323155-index.html Edgar Link pending
0001193125-18-323155.txt Edgar Link pending
0001193125-18-323155-xbrl.zip Edgar Link pending
d623821d10q.htm Edgar Link pending
d623821dex101.htm Edgar Link pending
d623821dex311.htm Edgar Link pending
d623821dex312.htm Edgar Link pending
d623821dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g623821snap0001.jpg Edgar Link pending
g623821snap0002.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ziop-20180930.xml Edgar Link completed
ziop-20180930.xsd Edgar Link pending
ziop-20180930_cal.xml Edgar Link unprocessable
ziop-20180930_def.xml Edgar Link unprocessable
ziop-20180930_lab.xml Edgar Link unprocessable
ziop-20180930_pre.xml Edgar Link unprocessable